Orum Therapeutics Appoints Dr Chad May as Chief Scientific Officer
Orum Therapeutics has appointed Dr Chad May, PhD, as Chief Scientific Officer (CSO), who brings over two decades of oncology and immunology research experience to advance the company’s degrader-antibody conjugate platform and pipeline of next-generation therapies.
Therapeutic Platforms | 05/01/2026 | By News Bureau | 131
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy